The incidence of melanoma is increasing, with 76 380 new cases of invasive melanoma and 68 480 new cases of melanoma in situ expected in 2016.
Objective
To review the contemporary management of early-stage melanoma.
Evidence Review
We searched PubMed, MEDLINE, and the Cochrane Database of Systematic Reviews databases from January 1, 2011, to May 1, 2016, yielding 966 articles. We focused our search on early-stage (melanoma in situ, stage I, and stage II) cutaneous melanoma. After excluding articles, 41 articles were manually reviewed. A review of the bibliographies of selected articles generated additional references.
Findings While the majority of recent advances have been in the treatment of advanced melanoma, surgical excision with margins based on the presence and depth of invasion continues to be the cornerstone of management. Sentinel lymph node biopsy plays a central role in the staging and treatment of melanoma.
Conclusions and Relevance
Accurate diagnosis and adequate surgical excision are critical in reducing local recurrences and improving outcomes. Sentinel lymph node biopsy is useful in staging the regional nodal basin and guiding treatment in appropriately selected patients.
Get full access to this article
View all access options for this article.
References
1.
American Cancer Society. Cancer Facts & Figures 2016. Atlanta, GA: American Cancer Society; 2016.
2.
SiegelRL, MillerKD, JemalA. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7-30. 26742998
3.
BichakjianCK, HalpernAC, JohnsonTM, ; American Academy of Dermatology. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2011; 65(5):1032-1047. 21868127
4.
AustinJR, ByersRM, BrownWD, WolfP. Influence of biopsy on the prognosis of cutaneous melanoma of the head and neck. Head Neck. 1996; 18(2):107-117. 8647675
5.
NgJC, SwainS, DowlingJP, WolfeR, SimpsonP, KellyJW. The impact of partial biopsy on histopathologic diagnosis of cutaneous melanoma: experience of an Australian tertiary referral service. Arch Dermatol. 2010; 146(3):234-239. 20231492
6.
GannonCJ, RousseauDLJr, RossMI, et al.Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer. 2006; 107(11):2647-2652. 17063497
7.
MartinRCII, ScogginsCR, RossMI, et al.Is incisional biopsy of melanoma harmful?. Am J Surg. 2005; 190(6):913-917. 16307945
8.
PflugfelderA, WeideB, EigentlerTK, et al.Incisional biopsy and melanoma prognosis: facts and controversies. Clin Dermatol. 2010; 28(3):316-318. 20541685
9.
KasprzakJM, XuYG. Diagnosis and management of lentigo maligna: a review. Drugs Context. 2015; 4:212281. 26082796
10.
KarimipourDJ, SchwartzJL, WangTS, et al.Microstaging accuracy after subtotal incisional biopsy of cutaneous melanoma. J Am Acad Dermatol. 2005; 52(5):798-802. 15858469
11.
BalchCM, GershenwaldJE, SoongSJ, et al.Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27(36):6199-6206. 19917835
12.
FranckenAB, ShawHM, ThompsonJF, et al.The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol. 2004; 11(4):426-433. 15070604
13.
NagoreE, OliverV, Botella-EstradaR, Moreno-PicotS, InsaA, ForteaJM. Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis. Melanoma Res. 2005; 15(3):169-177. 15917698
14.
ThompsonJF, SoongSJ, BalchCM, et al.Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011; 29(16):2199-2205. 21519009
15.
DonizyP, KaczorowskiM, LeskiewiczM, et al.Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: a 5-year survival analysis. Oncol Rep. 2014; 32(6):2735-2743. 25310673
16.
PatrawalaS, MaleyA, GreskovichC, et al.Discordance of histopathologic parameters in cutaneous melanoma: clinical implications. J Am Acad Dermatol. 2016; 74(1):75-80. 26514601
17.
FerringerT. Update on immunohistochemistry in melanocytic lesions. Dermatol Clin. 2012; 30(4):567-579. 23021046
18.
MagroCM, YangSE, ZippinJH, ZembowiczA. Expression of soluble adenylyl cyclase in lentigo maligna: use of immunohistochemistry with anti-soluble adenylyl cyclase antibody (R21) in diagnosis of lentigo maligna and assessment of margins. Arch Pathol Lab Med. 2012; 136(12):1558-1564. 23194049
19.
SolkyAC, ZembowiczA. Soluble adenylyl cyclase antibody (R21) as a diagnostic adjunct in the evaluation of lentigo maligna margins during slow Mohs surgery. Am J Dermatopathol. 2014; 36(11):882-887. 24698940
20.
NagarajanP, TetzlaffMT, CurryJL, PrietoVG. Use of new techniques in addition to IHC applied to the diagnosis of melanocytic lesions, with emphasis on CGH, FISH, and mass spectrometry [published online June 22, 2016]. Actas Dermosifiliogr. doi:10.1016/j.ad.2016.05.005. 27344067
21.
Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015; 161(7):1681-1696. 26091043
22.
ErmanAB, CollarRM, GriffithKA, et al.Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma. Cancer. 2012; 118(4):1040-1047. 21773971
23.
MortonDL, CochranAJ, ThompsonJF, ; Multicenter Selective Lymphadenectomy Trial Group. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005; 242(3):302-311. 16135917
24.
MortonDL, WenDR, WongJH, et al.Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992; 127(4):392-399. 1558490
25.
StoffelsI, BoyC, PöppelT, et al.Association between sentinel lymph node excision with or without preoperative SPECT/CT and metastatic node detection and disease-free survival in melanoma. JAMA. 2012; 308(10):1007-1014. 22968889
26.
DandekarM, LoweL, FullenDR, et al.Discordance in histopathologic evaluation of melanoma sentinel lymph node biopsy with clinical follow-up: results from a prospectively collected database. Ann Surg Oncol. 2014; 21(11):3406-3411. 24845727
27.
O’BrienCJ, UrenRF, ThompsonJF, et al.Prediction of potential metastatic sites in cutaneous head and neck melanoma using lymphoscintigraphy. Am J Surg. 1995; 170(5):461-466. 7485733
28.
WillisAI, RidgeJA. Discordant lymphatic drainage patterns revealed by serial lymphoscintigraphy in cutaneous head and neck malignancies. Head Neck. 2007; 29(11):979-985. 17525953
FariesMB, ThompsonJF, CochranA, ; MSLT Cooperative Group. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol. 2010; 17(12):3324-3329. 20614193
31.
MortonDL, ThompsonJF, CochranAJ, ; MSLT Group. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014; 370(7):599-609. 24521106
32.
BegerJ, HanselG, KrönertC, et al.A 10-year analysis of primary cutaneous malignant melanoma with sentinel lymph node biopsy and long-term follow-up. Int J Dermatol. 2013; 52(2):220-230. 23347311
33.
MortonDL, ThompsonJF, CochranAJ, ; MSLT Group. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006; 355(13):1307-1317. 17005948
34.
VermeerenL, Valdés OlmosRA, KlopWM, et al.SPECT/CT for sentinel lymph node mapping in head and neck melanoma. Head Neck. 2011; 33(1):1-6. 20848414
35.
Jimenez-HeffernanA, EllmannA, SadoH, et al.Results of a prospective multicenter International Atomic Energy Agency sentinel node trial on the value of SPECT/CT over planar imaging in various malignancies. J Nucl Med. 2015; 56(9):1338-1344. 26229148
36.
SulzbacherL, KlingerM, ScheureckerC, et al.Clinical usefulness of a novel freehand 3D imaging device for radio-guided intraoperative sentinel lymph node detection in malignant melanoma. Clin Nucl Med. 2015; 40(9):e436-e440. 26164178
37.
NakamuraY, FujisawaY, NakamuraY, et al.Improvement of the sentinel lymph node detection rate of cervical sentinel lymph node biopsy using real-time fluorescence navigation with indocyanine green in head and neck skin cancer. J Dermatol. 2013; 40(6):453-457. 23621899
38.
FujisawaY, NakamuraY, KawachiY, OtsukaF. Indocyanine green fluorescence-navigated sentinel node biopsy showed higher sensitivity than the radioisotope or blue dye method, which may help to reduce false-negative cases in skin cancer. J Surg Oncol. 2012; 106(1):41-45. 22252373
39.
FujisawaY, NakamuraY, KawachiY, OtsukaF. A custom-made, low-cost intraoperative fluorescence navigation system with indocyanine green for sentinel lymph node biopsy in skin cancer. Dermatology. 2011; 222(3):261-268. 21502752
40.
GilmoreDM, KhullarOV, GiouxS, et al.Effective low-dose escalation of indocyanine green for near-infrared fluorescent sentinel lymph node mapping in melanoma. Ann Surg Oncol. 2013; 20(7):2357-2363. 23440551
41.
van der VorstJR, SchaafsmaBE, VerbeekFP, et al.Dose optimization for near-infrared fluorescence sentinel lymph node mapping in patients with melanoma. Br J Dermatol. 2013; 168(1):93-98. 23078649
42.
StoffelsI, von der StückH, BoyC, et al.Indocyanine green fluorescence-guided sentinel lymph node biopsy in dermato-oncology. J Dtsch Dermatol Ges. 2012; 10(1):51-57. 22103392
43.
van den BergNS, BrouwerOR, SchaafsmaBE, et al.Multimodal surgical guidance during sentinel node biopsy for melanoma: combined gamma tracing and fluorescence imaging of the sentinel node through use of the hybrid tracer indocyanine green-99mTc-nanocolloid. Radiology. 2015; 275(2):521-529. 25521776
44.
BrouwerOR, BuckleT, VermeerenL, et al.Comparing the hybrid fluorescent-radioactive tracer indocyanine green-99mTc-nanocolloid with 99mTc-nanocolloid for sentinel node identification: a validation study using lymphoscintigraphy and SPECT/CT. J Nucl Med. 2012; 53(7):1034-1040. 22645297
45.
VeronesiU, CascinelliN, AdamusJ, et al.Thin stage I primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm. N Engl J Med. 1988; 318(18):1159-1162. 3079582
46.
Cohn-CedermarkG, RutqvistLE, AnderssonR, et al.Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer. 2000; 89(7):1495-1501. 11013363
47.
KhayatD, RixeO, MartinG, ; French Group of Research on Malignant Melanoma. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer. 2003; 97(8):1941-1946. 12673721
48.
GillgrenP, DrzewieckiKT, NiinM, et al.2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet. 2011; 378(9803):1635-1642. 22027547
49.
BalchCM, SoongSJ, SmithT, ; Investigators from the Intergroup Melanoma Surgical Trial. Long-term results of a prospective surgical trial comparing 2 cm vs 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol. 2001; 8(2):101-108. 11258773
50.
ThomasJM, Newton-BishopJ, A’HernR, ; United Kingdom Melanoma Study Group; British Association of Plastic Surgeons; Scottish Cancer Therapy Network. Excision margins in high-risk malignant melanoma. N Engl J Med. 2004; 350(8):757-766. 14973217
51.
CoitDG, ThompsonJA, AlgaziA, et al.Melanoma, version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016; 14(4):450-473. 27059193
52.
SladdenMJ, BalchC, BarzilaiDA, et al.Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev. 2009;(4):CD004835. 19821334
53.
MocellinS, PasqualiS, NittiD. The impact of surgery on survival of patients with cutaneous melanoma: revisiting the role of primary tumor excision margins. Ann Surg. 2011; 253(2):238-243. 21173691
54.
LensMB, DawesM, GoodacreT, BishopJA. Excision margins in the treatment of primary cutaneous melanoma: a systematic review of randomized controlled trials comparing narrow vs wide excision. Arch Surg. 2002; 137(10):1101-1105. 12361412
55.
RawlaniR, RawlaniV, QureshiHA, KimJY, WayneJD. Reducing margins of wide local excision in head and neck melanoma for function and cosmesis: 5-year local recurrence-free survival. J Surg Oncol. 2015; 111(7):795-799. 25712156
56.
CohenLM. Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol. 1995; 33(6):923-936. 7490362
57.
PatelAN, PerkinsW, LeachIH, VarmaS. Johnson square procedure for lentigo maligna and lentigo maligna melanoma. Clin Exp Dermatol. 2014; 39(5):570-576. 24934910
58.
MoyerJS, RudyS, BoonstraPS, et al.Efficacy of staged excision with permanent section margin control for cutaneous head and neck melanoma [published online December 21, 2016]. JAMA Dermatol. doi:10.1001/jamadermatol.2016.4603.
59.
JohnsonTM, HeadingtonJT, BakerSR, LoweL. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the “square” procedure. J Am Acad Dermatol. 1997; 37(5, pt 1):758-764. 9366823
60.
HumphreysRE, HillmanGG, von HofeE, XuM. Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy. Cell Mol Immunol. 2004; 1(3):180-185. 16219165
61.
BosbousMW, DzwierzynskiWW, NeuburgM. Staged excision of lentigo maligna and lentigo maligna melanoma: a 10-year experience. Plast Reconstr Surg. 2009; 124(6):1947-1955. 19952650
62.
MöllerMG, Pappas-PolitisE, ZagerJS, et al.Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol. 2009; 16(6):1526-1536. 19050971
63.
HazanC, DuszaSW, DelgadoR, BusamKJ, HalpernAC, NehalKS. Staged excision for lentigo maligna and lentigo maligna melanoma: a retrospective analysis of 117 cases. J Am Acad Dermatol. 2008; 58(1):142-148. 18029055
64.
HuilgolSC, SelvaD, ChenC, et al.Surgical margins for lentigo maligna and lentigo maligna melanoma: the technique of mapped serial excision. Arch Dermatol. 2004; 140(9):1087-1092. 15381549
65.
BubJL, BergD, SleeA, OdlandPB. Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up. Arch Dermatol. 2004; 140(5):552-558. 15148099
66.
DemirciH, JohnsonTM, FruehBR, MuschDC, FullenDR, NelsonCC. Management of periocular cutaneous melanoma with a staged excision technique and permanent sections: the square procedure. Ophthalmology. 2008; 115(12):2295-2300. 18692248
67.
ArnonO, RapiniRP, MamelakAJ, GoldbergLH. Mohs micrographic surgery: current techniques. Isr Med Assoc J. 2010; 12(7):431-435. 20862826
68.
KunishigeJH, BrodlandDG, ZitelliJA. Surgical margins for melanoma in situ. J Am Acad Dermatol. 2012; 66(3):438-444. 22196979
69.
EtzkornJR, SobankoJF, ElenitsasR, et al.Low recurrence rates for in situ and invasive melanomas using Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining: tissue processing methodology to optimize pathologic staging and margin assessment. J Am Acad Dermatol. 2015; 72(5):840-850. 25774012
70.
McGuireLK, DisaJJ, LeeEH, BusamKJ, NehalKS. Melanoma of the lentigo maligna subtype: diagnostic challenges and current treatment paradigms. Plast Reconstr Surg. 2012; 129(2):288e-299e. 22286443
71.
WallingHW, ScuphamRK, BeanAK, CeilleyRI. Staged excision versus Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol. 2007; 57(4):659-664. 17870430
72.
BienertTN, TrotterMJ, ArletteJP. Treatment of cutaneous melanoma of the face by Mohs micrographic surgery. J Cutan Med Surg. 2003; 7(1):25-30. 12447624
73.
PrietoVG, ArgenyiZB, BarnhillRL, et al.Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions?. Am J Clin Pathol. 2003; 120(2):203-208. 12931550
